These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37770228)

  • 1. Differential Effects of Clotrimazole on X-Ray Crystal Structures of Human Cytochromes P450 3A5 and 3A4.
    Hsu MH; Johnson EF
    Drug Metab Dispos; 2023 Dec; 51(12):1642-1650. PubMed ID: 37770228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.
    Hsu MH; Johnson EF
    J Biol Chem; 2019 May; 294(20):8015-8022. PubMed ID: 30926609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
    Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
    Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.
    Niwa T; Yasumura M; Murayama N; Yamazaki H
    Drug Metab Lett; 2014; 8(1):43-50. PubMed ID: 24484539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5.
    Niwa T; Narita K; Okamoto A; Murayama N; Yamazaki H
    J Pharm Pharm Sci; 2019; 22(1):332-339. PubMed ID: 31339834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5.
    Hsu MH; Johnson EF
    J Biol Chem; 2022 May; 298(5):101909. PubMed ID: 35398097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450.
    Lee JY; Kang NS; Kang YK
    Biopolymers; 2012 Apr; 97(4):219-28. PubMed ID: 22113809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5.
    Wang J; Buchman CD; Seetharaman J; Miller DJ; Huber AD; Wu J; Chai SC; Garcia-Maldonado E; Wright WC; Chenge J; Chen T
    J Am Chem Soc; 2021 Nov; 143(44):18467-18480. PubMed ID: 34648292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.
    Khan KK; He YQ; Correia MA; Halpert JR
    Drug Metab Dispos; 2002 Sep; 30(9):985-90. PubMed ID: 12167563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
    McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
    Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of CYP3A4 with caffeine: First insights into multiple substrate binding.
    Sevrioukova IF
    J Biol Chem; 2023 Sep; 299(9):105117. PubMed ID: 37524132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs.
    Ouellet H; Podust LM; de Montellano PR
    J Biol Chem; 2008 Feb; 283(8):5069-80. PubMed ID: 18089574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational insights into the different catalytic activities of CYP3A4 and CYP3A5 toward schisantherin E.
    Xue Y; Li J; Wu Z; Liu G; Tang Y; Li W
    Chem Biol Drug Des; 2019 May; 93(5):854-864. PubMed ID: 30637977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
    Saba N; Seal A
    J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.
    Wright WC; Chenge J; Wang J; Girvan HM; Yang L; Chai SC; Huber AD; Wu J; Oladimeji PO; Munro AW; Chen T
    J Med Chem; 2020 Feb; 63(3):1415-1433. PubMed ID: 31965799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ir(III)-Based Agents for Monitoring the Cytochrome P450 3A4 Active Site Occupancy.
    Denison M; Steinke SJ; Majeed A; Turro C; Kocarek TA; Sevrioukova IF; Kodanko JJ
    Inorg Chem; 2022 Sep; 61(35):13673-13677. PubMed ID: 35994607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7.
    Godamudunage MP; Grech AM; Scott EE
    Drug Metab Dispos; 2018 Sep; 46(9):1329-1337. PubMed ID: 29991575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in Mechanism-Based Inhibition of Cytochrome P450 3A4 and 3A5 by a Series of Fluoroquinolone Antibacterial Agents.
    Watanabe A; Takakusa H; Kimura T; Inoue SI; Kusuhara H; Ando O
    Drug Metab Dispos; 2017 Mar; 45(3):336-341. PubMed ID: 27974381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced Fit Describes Ligand Binding to Membrane-Associated Cytochrome P450 3A4.
    Sweeney DT; Zárate-Pérez F; Stokowa-Sołtys K; Hackett JC
    Mol Pharmacol; 2023 Oct; 104(4):154-163. PubMed ID: 37536953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.